Enbrel and Systemic lupus erythematosus - a phase IV clinical study of FDA data

Summary:

Systemic lupus erythematosus is found among people who take Enbrel, especially for people who are female, 40-49 old, have been taking the drug for 1 - 6 months.

The phase IV clinical study analyzes which people take Enbrel and have Systemic lupus erythematosus. It is created by eHealthMe based on reports of 633,316 people who have side effects when taking Enbrel from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Jan, 03, 2023

633,316 people reported to have side effects when taking Enbrel.
Among them, 8,359 people (1.32%) have Systemic lupus erythematosus.

What is Enbrel?

Enbrel has active ingredients of etanercept. It is often used in rheumatoid arthritis. eHealthMe is studying from 635,038 Enbrel users for its effectiveness, alternative drugs and more.

What is Systemic lupus erythematosus?

Systemic lupus erythematosus (an autoimmune disease, which means the body's immune system mistakenly, attacks healthy tissue) is found to be associated with 2,194 drugs and 1,493 conditions by eHealthMe.

Number of Enbrel and Systemic lupus erythematosus reports submitted per year:

Could Enbrel cause Systemic lupus erythematosus?

* Approximation only. Some reports may have incomplete information.

Do you take Enbrel and have Systemic lupus erythematosus?

Check whether Systemic lupus erythematosus is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Hania A, "Pyoderma Gangrenosum in a Patient With Systemic Lupus Erythematosus: Case Report", Journal of Medical Cases, 2014 Aug .
Hu P, Lu L, Hu B, Deng F, Fei WJ, "Cyclophosphamide‐Induced Hypertensive Encephalopathy in a Young Girl With Lupus", The Journal of Clinical Hypertension, 2012 Apr .

Related studies

How severe was Systemic lupus erythematosus and when was it recovered:

Systemic lupus erythematosus in Enbrel

Expand to all the drugs that have ingredients of etanercept:

Systemic lupus erythematosus and drugs with ingredients of etanercept (3,741 reports)

Alternative drugs to, pros and cons of Enbrel:

Enbrel (635,038 reports)

Common Enbrel side effects:

Browse all side effects of Enbrel:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Systemic lupus erythematosus treatments and more:

Systemic lupus erythematosus (61,960 reports)

COVID vaccines that are related to Systemic lupus erythematosus:

Common drugs associated with Systemic lupus erythematosus:

All the drugs that are associated with Systemic lupus erythematosus:

Systemic lupus erythematosus (2,194 drugs)

Common conditions associated with Systemic lupus erythematosus:

Rheumatoid arthritis: 10,615 reports
Crohn's disease: 1,632 reports
Psoriasis: 1,457 reports
Multiple sclerosis: 823 reports
High blood pressure: 742 reports

All the conditions that are associated with Systemic lupus erythematosus:

Systemic lupus erythematosus (1,493 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on etanercept (the active ingredients of Enbrel) and Enbrel (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.